AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00615186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuradiab + Radiotherapy + Temozolomide
Description: Prior Surgery~Rickham Catheter placement 99mTc-DTPA Flow Study~Neuradiab Dosimetry Study~Neuradiab Therapeutic Dose Administration~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + temozolomide (75 mg/m2/day) over 6.5 weeks.~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment.
Study NCT00615186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy + Temozolomide
Description: Prior Surgery: Gross total resection (\< 1 cm. enhancing rim)~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + 42 days of temozolomide (75 mg/m2/day) over 6.5 weeks~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment.
Study NCT06212908 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Basic Periodontal Therapy
Description: All patients received oral hygiene instructions (interproximal cleaning with floss and interdental brushes, brushing instructions on the Bass technique). The patients were also encouraged to brush the back of the tongue once a day. Subsequently, all patients underwent supragingival scaling, prophylaxis, and polishing. Supragingival scaling was performed using manual instruments (Gracey curettes) and an ultrasonic device.
Study NCT05163613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: magnetostimulation
Description: Treatment parameters: 12 minutes M2P2 program, with increasing intensity from 1 to 8. The authors applied magnetic field with a frequency of 180 - 190 Hz, pulse packet frequencies between 12.5 and 29 Hz, packet groups 2.8 - 7.6 Hz, series 0.08 - 0.3 Hz, with magnetic induction B= 3.2 µT (on average) and B = 40 µT at a pulse peak.
Study NCT05163613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: Standard therapy used in all patients consisted of the use of pharmacological agents necessary to treat the viral infection (antiviral drugs, antibiotics, dexamethasone) and the inclusion of proper care, education, occupational therapy, self-service learning, breathing exercises and motor mobilization.
Study NCT01626222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Exemestane according to the individual label. Commercially available Exemestane will be supplied as tablets of 25 mg strength for oral administration. Complete guidelines for management and administration of Exemestane can be found in the package insert. Exemestane will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet of 25 mg Exemestane orally. Package insert instructions should be followed. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Exemestane exactly as prescribed.
Study NCT01626222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: Everolimus (RAD001) is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Everolimus according to the individual label. Everolimus is formulated as tablets of 10 and 5 mg strength for oral administration. All study medication will be packaged into blister packs. The blisters should be opened only at the time of administration, as the drugs are both hygroscopic and light sensitive. Everolimus will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet × 10 mg Everolimus orally with a large glass of water once daily at the same time each day with or without food. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Everolimus exactly as prescribed.
Study NCT03782090 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endobronchial intubation
Description: 1. In control group, endobronchial intubation is performed using conventional technique with left-sided double-lumen endobronchial tube(Shiley®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. The tube is advanced according to the depth(cm) of the tube calculated by the height of patient(12.5+0.1\*height). Afterwards, the depth of the tube is adjusted by the compliance of both lung.~2. In experimental group, patients are intubated with novel double-lumen endobronchial tube(Ankor®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. Once the carinal cuff of the tube is passed through the vocal cord of patients, the carinal cuff is inflated with 5-8ml of air. The tube is advanced until the tube stops itself at some point along the tracheobronchial tree. And then the carinal cuff is deflated.
Study NCT03782090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial intubation
Description: 1. In control group, endobronchial intubation is performed using conventional technique with left-sided double-lumen endobronchial tube(Shiley®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. The tube is advanced according to the depth(cm) of the tube calculated by the height of patient(12.5+0.1\*height). Afterwards, the depth of the tube is adjusted by the compliance of both lung.~2. In experimental group, patients are intubated with novel double-lumen endobronchial tube(Ankor®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. Once the carinal cuff of the tube is passed through the vocal cord of patients, the carinal cuff is inflated with 5-8ml of air. The tube is advanced until the tube stops itself at some point along the tracheobronchial tree. And then the carinal cuff is deflated.
Study NCT03226964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal oxygen
Description: humidified high flow nasal oxygen
Study NCT03226964 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high flow nasal oxygen
Description: humidified high flow nasal oxygen
Study NCT01974037 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Description: Capsaicin in the concentration of 0.5 µmol/L was mixed in the test solutions in Capsaicin_effect subgroups
Study NCT01974037 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Capsaicin in the concentration of 0.5 µmol/L was mixed in the test solutions in Capsaicin_effect subgroups
Study NCT01974037 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NaCl
Description: NaCl in various concentrations was desorved in the test solutions in Salt_effect subgroups
Study NCT02666287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT/FF
Description: BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.
Study NCT00998075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: Tablet, oral, single dose
Study NCT01864070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraSphere
Description: TheraSphere glass microspheres containing Y-90 injected into catheter, and will deliver 120 Gy to entire tumor bearing portion of the liver given at a single session on Cycle 1 Day 15.
Study NCT01864070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Starting dose: is 5 mg by mouth daily for cycles 1 and 2. Patients will receive standard dose of Everolimus at 10 mg by mouth daily starting cycle 3 day 1.~Dose Expansion Cohort Starting Dose: Maximum tolerated dose from dose escalation cohort.
Study NCT01864070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: At least 1 time a week by phone or at the clinic for up to 30 days after last everolimus dose, study staff will follow up. Patient asked about any side effects they may have had. The call should last about 10-15 minutes.
Study NCT03100968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palpation
Description: Traditional epidural methods used for the identification of the midline using palpation prior to procedure
Study NCT03100968 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Lumbar spinal ultrasound performed for identification of the midline prior to procedure.
Study NCT02984761 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy
Description: Stereotactic radiotherapy uses high doses of ionizing energy to treat cancer cells with image guidance. The treatment is delivered in an outpatient setting, and for purposes of this trial is delivered in 3-5 fractions.
Study NCT02984761 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomic Pulmonary Resection
Description: An anatomic pulmonary resection is an oncologic procedure that dissects out an anatomically defined segment of the lung to remove all of the lung tissue around a lung tumor. It requires an operation with general anesthesia, with a short hospital stay. The procedure entails removal of lymph nodes inside the chest that might not be easily accessible without an operation.
Study NCT02034981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Patients will receive oral crizotinib, daily continuously, until progression or unacceptable toxicity develops.~-250 mg twice daily for adults ≥ 18 years of age~* 280 mg/m² twice daily for children and adolescents aged from 1 to 17 (except ALCL).~* 165 mg/m² twice daily for ALCL patients aged from 1 to 17.
Study NCT02666287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT
Description: BAT is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose appear as dry white powder. Second strip contains lactose which appear as a dry white powder.
Study NCT01116648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo optional tissue biopsy
Study NCT01116648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo optional tissue biopsy
Study NCT01116648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT01116648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT01116648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO
Study NCT01116648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT02666287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose which appear as dry white powder.
Study NCT02666287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF (MgSt)
Description: FF magnesium stearate is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose with magnesium stearate which appear as dry white powder.
Study NCT02666287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/Vilanterol
Description: FF/Vilanterol is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 25 mcg per blister of vilanterol blended with lactose and magnesium stearate appear as dry white powder and second strip contains 100 mcg per blister of FF blended with lactose which appear as dry white powder.
Study NCT01116648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT01116648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT04573257 — intervention group
Intervention type: OTHER
Intervention: Echocardiography and pulse wave velocity measurement
Description: Echocardiography(Conventional ultrasonic imaging,tissue Doppler imaging and non invasive myocardial work) and pulse wave velocity measurement
Study NCT00295763 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Thyrogen (thyrotropin alfa for injection)
Description: No reference therapy was given. All patients in this follow-up study received Thyrogen. Thyrogen 0.9 mg was administered intramuscularly (IM) in the buttock on 2 consecutive days.~For WBS and static neck imaging, each patient received 4 mCi (148 MBq) ± 0.4 mCi 131I PO.
Study NCT03761537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
Study NCT03761537 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Study NCT02850432 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive treatment
Description: Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol
Study NCT02850432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: rehabilitation with medical therapy
Study NCT03761498 — intervention group
Intervention type: OTHER
Intervention: Caloric Requirement
Description: Infants will be provided standard of care and given calories required to maintain appropriate growth per unit policies already in place.
Study NCT02317939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instruction
Description: online instruction tutorials at followup visits
Study NCT02317939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard baseline instruction
Description: self-guidance at followup visits
Study NCT00328614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samarium-153
Description: Samarium-153 will be administered as a single dose after one month of hormonal therapy. The dose level of Samarium-153 may change to determine maximum tolerated dose (MTD).
Study NCT00328614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Androgen Suppression (TAS) with Bicalutamide
Description: Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
Study NCT00328614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total androgen suppression (TAS) with Goserelin Acetate
Description: Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
Study NCT01116648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT01116648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT01116648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT01116648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT01116648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT01116648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT01116648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Given PO
Study NCT02137850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol
Description: For intravenous (i.v.) injection. Frequency and dosage (20-75 U/kg) dependent on whether given as treatment for bleeding episode or as prophylaxis
Study NCT00328614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will begin 3 months following the initiation of hormone administration. Daily tumor doses will be given 5 days per week for 7-8 weeks.
Study NCT00761280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabedersen
Study NCT00761280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Study NCT00761280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug delivery system for administration of AP 12009
Description: Drug delivery system for Convection Enhanced Delivery consists of a portable pump (Pegasus vario or Pega vario) with drug reservoir (Pega Bag) and infusion line (Pega Line). Main implanted parts are the port access system (PORT-A-CATH) and the intratumoral catheter (Medtronic ventricular catheter).
Study NCT00761280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of Drug Delivery System
Description: Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
Study NCT00761280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carmustine
Study NCT00761280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lomustine
Study NCT03565042 — intervention group
Intervention type: PROCEDURE
Intervention: Arthroscopy
Description: Arthroscopy of swollen joint (ankle/knee)
Study NCT01489254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate (GTR)
Description: Glatiramer Acetate (GTR) 20 mg daily, for 9 months (Part 1) followed by additional 15 month treatment period (Part 2)
Study NCT01489254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer Acetate (Copaxone®)
Description: Glatiramer Acetate (Copaxone), 20 mg daily, for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
Study NCT01489254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (daily) for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
Study NCT04623034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ademetionine
Study NCT03263832 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Antibiofilmogramme
Description: An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
Study NCT03072238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Oral tablets, 400 mg, given once daily (QD) beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.
Study NCT03072238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Oral tablets of abiraterone, 1000 mg QD, taken on an empty stomach and swallowed whole with water.
Study NCT03072238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Oral tablets of abiraterone, 1000 mg QD, taken on an empty stomach and swallowed whole with water.
Study NCT03072238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral tablets (matched to ipatasertib appearance), given QD beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.
Study NCT03072238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone/Prednisolone
Description: Oral tablets of 5 mg, taken twice daily (BID) until disease progression or intolerable toxicity.
Study NCT03072238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone/Prednisolone
Description: Oral tablets of 5 mg, taken twice daily (BID) until disease progression or intolerable toxicity.
Study NCT01959347 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Miduretheral Sling
Description: MUS can include the TVT™ (mechanical cut mesh only, Gynecare, ETHICON Women's Health \& Urology, Somerville, NJ), TVT-O™ (mechanical cut mesh only, Gynecare), or Monarc™ (American Medical Systems, Minnetonka, MN).